Semaglutide-Glycine-Cyanocobalamin Injectable, 2.5 mg, 5 mg, 1 MG/ML, 0.5 mL vials, Rx only, Northwest Compounders, Beaverton, OR
FDA recall notice · announced April 22, 2026 · Payless Compounders
Class II FDA/FSIS Class II: use may cause temporary or medically reversible adverse health consequences.
The product
Semaglutide-Glycine-Cyanocobalamin Injectable, 2.5 mg, 5 mg, 1 MG/ML, 0.5 mL vials, Rx only, Northwest Compounders, Beaverton, OR
Reason for recall
Lack of Assurance of Sterility
Notes
Distribution: OR
Lot/code information: Lot Number 01-27-2026@14S.5
Quantity: 91 vials
Status: Ongoing
Products in this recall event:
- Semaglutide-Glycine-Cyanocobalamin Injectable, 2.5 mg, 5 mg, 1 MG/ML, 0.5 mL vials, Rx only, Northwest Compounders, Beaverton, OR (D-0471-2026)
Source: U.S. Food and Drug Administration public recall data. This page reports official records and is not legal, medical, or repair advice.